



August 29, 2014

Dear Steele Family and Friends,

Another year has gone by, and once again I would like to sincerely thank you for your donations through the Christopher Steele Foundation benefiting sarcoma research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. I am extremely appreciative for your continued fundraising efforts and support and would like to congratulate you on your continued success.

The Robert H. Lurie Comprehensive Cancer Center continues to excel at the treatment of patients with soft tissue sarcomas on and off of clinical trials. We are committed to the newest, most sophisticated therapies and are thrilled to offer our patients the latest and greatest in medical research.

One clinical trial currently funded by the Christopher Steele Foundation that I would like to highlight is titled "*Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma*". This study is for patients who have a type of cancer called angiosarcoma that has gotten worse after they received chemotherapy, or angiosarcoma patients who have not responded to standard chemotherapy. The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma.

A second trial funded by the Christopher Steele Foundation is titled "*A Phase II Study of Tivozanib in Patients with Metastatic and Non-resectable Soft Tissue Sarcomas*". This study is for patients who have been diagnosed with soft tissue sarcoma that has spread (metastasized) or that is not eligible for removal by surgery. The purpose of this study is to determine how soft tissue sarcomas respond to treatment with an investigational drug called tivozanib.

We are constantly building upon our participation in clinical trials and aim to offer effective and novel therapies to our patients. Private fundraising efforts are crucial towards maintaining our robust program at Northwestern, and every penny raised is used to support the mission set forward and carried out through the Christopher Steele Foundation.

Again, on behalf of my staff and those who will benefit from your generous donations, I thank you.

Sincerely,

A handwritten signature in black ink, appearing to read "Mark Agulnik".

Mark Agulnik, MD
Associate Professor

cc: David Sack, Vice President, Northwestern Memorial Foundation